Antibody Formulation Stability via Citrate Trehalose Polysorbate

The patent optimizes multiple formulation parameters including pH (5.0-7.5), antibody concentration (10-100 mg/mL), and excipient concentrations to achieve stable formulations. Specific parameters like citrate buffer concentration (5-50 mM), trehalose concentration (50-500 mM), and polysorbate 20 concentration (0.001-0.1%) are systematically adjusted to prevent aggregation and maintain antibody stability while effectively targeting alpha-synuclein.

The formulation combines multiple components working synergistically: the anti-alpha-synuclein antibody (9E4 or variants) provides specific binding, citrate buffer maintains pH stability, trehalose acts as a stabilizing excipient and protective agent, and polysorbate 20 prevents aggregation. This composite formulation approach creates a stable therapeutic product that effectively addresses alpha-synuclein toxicity.

The patent establishes an optimized concentration range for the antibody (10-100 mg/mL, preferably 20-50 mg/mL) and adjusts other formulation parameters accordingly. At these concentrations, the formulation maintains both therapeutic effectiveness and stability through the synergistic action of excipients. The citrate buffer concentration (5-50 mM) and trehalose concentration (50-500 mM) are specifically tuned to prevent aggregation at these antibody concentrations.

Trehalose and polysorbate 20 act as intermediary substances that mediate between the antibody and the aqueous environment. Trehalose provides steric stabilization and prevents protein-protein interactions that lead to aggregation, while polysorbate 20 reduces surface tension and prevents adsorption to container surfaces. These intermediaries enable the formulation to maintain stability at high antibody concentrations required for therapeutic effectiveness.

The patent specifies precise concentration ranges for each excipient to achieve stability: citrate buffer (5-50 mM), trehalose (50-500 mM), and polysorbate 20 (0.001-0.1%). These optimized parameters ensure formulation stability while providing clear manufacturing guidelines. The pH is maintained between 5.0-7.5, which is achievable with standard buffer systems and does not require complex processing equipment.

Each excipient performs a specific localized function: citrate buffer controls pH locally, trehalose provides molecular-level stabilization of the antibody structure, and polysorbate 20 acts at interfaces to prevent aggregation. This targeted approach allows the use of simple, well-characterized excipients rather than complex stabilization systems, reducing manufacturing complexity while maintaining formulation stability.